Status:

RECRUITING

Onlay Versus Inlay Humeral Component in Reverse Total Shoulder Arthroplasty

Lead Sponsor:

Corewell Health East

Collaborating Sponsors:

Stryker Nordic

Conditions:

Arthritis Shoulder

Rotator Cuff Injuries

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this study is to compare the effect of different ways to place the component that goes at the top of the humerus (upper arm) in reverse total shoulder replacement. Some surgeons place the ...

Detailed Description

This study aims to determine if active external rotation two years postoperatively varies based on whether an inlay or onlay humeral component is used in reverse shoulder arthroplasty (RTSA). The stud...

Eligibility Criteria

Inclusion

  • Patients undergoing primary reverse total shoulder arthroplasty with the following components:
  • Onlay group: Ascend Flex stem, Perform Reversed standard +3 lateralized 25mm baseplate with standard 36 mm glenosphere or +6 lateralized 25mm baseplate with 39mm glenosphere
  • Inlay group: Perform Stem Reverse, Perform Reversed +3 lateralized 25mm baseplate with standard 36mm glenosphere or +6 lateralized 25mm baseplate with 39mm glenosphere
  • Diagnosis of cuff tear arthropathy, massive cuff tear, or primary osteoarthritis with cuff tear
  • Negative external rotation lag sign, ability to externally rotate beyond neutral
  • Age 18 years or older

Exclusion

  • Revision arthroplasty
  • Prior open shoulder surgery
  • Concomitant tendon transfer (Latissimus Dorsi, Pectoralis Tendon, Lower Trapezius)
  • Diagnosis of rheumatoid arthritis, infection, acute trauma or instability
  • Patients not willing to undergo a standardized physical therapy protocol or home therapy program after surgical intervention
  • Patient anatomy does not accommodate the study implants per surgeon discretion
  • Pregnant, patient-reported
  • Minors (under 18 years of age)
  • Cognitively impaired based on a diagnosis of dementia, psychiatric disorder, or any cognitive deficit that will not allow for proper informed consent or answering of study questionnaires

Key Trial Info

Start Date :

October 20 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

154 Patients enrolled

Trial Details

Trial ID

NCT05297305

Start Date

October 20 2023

End Date

December 1 2025

Last Update

November 4 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

William Beaumont Hospital

Royal Oak, Michigan, United States, 48073